Safety and effectiveness of biphasic insulin aspart 30 in different age-groups: a1chieve sub-analysis.

ABSTRACT:

Introduction

Effective management of type 2 diabetes requires sustained glycemic control over many years, which can be particularly challenging for elderly people. This sub-analysis of the A1chieve study evaluated the clinical safety and effectiveness of biphasic insulin aspart 30 in 3 age-groups (≤40, >40-65, and >65 years) of previously insulin-experienced and insulin-naïve people with type 2 diabetes.

Methods

A1chieve was an international, multicenter, prospective, open-label, non-interventional, 24-week study in people with type 2 diabetes who had been receiving anti-diabetes medication before starting, or switching to, therapy with biphasic insulin aspart 30, insulin detemir or insulin aspart (alone or in combination) in routine clinical practice. This sub-analysis eval

SUBMITTER: Khamseh ME 

PROVIDER: S-EPMC3889316 | biostudies-literature | 2013 Dec

REPOSITORIES: biostudies-literature